Drug Approval | June 03, 2026
FDA fast-tracks Roche’s giredestrant review as data signal potential shift in early breast cancer care
The filing is backed by Phase III data from the lidERA Breast Cancer study
The filing is backed by Phase III data from the lidERA Breast Cancer study
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
The facility sets a new benchmark in respiratory diagnostics
Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets
The safety profile was described as manageable, though not without notable toxicities
Fertility platform launches flagship clinic with advanced IVF tech
Approved as a web-based pre-diagnostic tool for suspected rare diseases and classified as a Class A (non-sterile and non-measuring) medical device
This marks one of the most closely watched oncology readouts at this year’s medical congress
Initiatives at Churchgate Station and Mahindra & Mahindra focus on early detection, public education, and tobacco-related cancer prevention
While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
